1-20 of 697
leukemia, myeloid, chronic-phase
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Accumulation of DNA Damage and Alteration of the DNA Damage Response in Chronic Myeloid Leukemia

Free
Henning D. Popp, Vanessa Kohl, MSc, Johanna Flach, PhD, Susanne Brendel, MTA, Helga Kleiner, MTA, Wolfgang Seifarth, PhD, Christel Weiss, PhD, Susanne Saussele, MD, Wolf-Karsten Hofmann, MD PhD, Alice Fabarius, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5364.
https://doi.org/10.1182/blood-2019-122698
Published: 2019
Journal Articles

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Free
Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD PhD, Kaichi Nishiwaki, MD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, MD PhD, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof., Junichi Sakamoto,, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof.
Journal: Blood
Blood (2019) 134 (Supplement_1): 4154.
https://doi.org/10.1182/blood-2019-130504
Published: 2019
Journal Articles

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Free
Ekin Kircali, Guldane Cengiz Seval, Sinem Civriz Bozdag, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Gunhan Gurman, MD, Osman Ilhan, Hamdi Akan, MD, Meral Beksac, MD, Pervin Topcuoglu, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4156.
https://doi.org/10.1182/blood-2019-127622
Published: 2019
Journal Articles

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Free
Naoto Takahashi, MD PhD, Itaru Matsumura, MD PhD, Shin Fujisawa, MD, Kenichi Ishizawa, MD PhD, Takaaki ONO, MD PhD, Emiko Sakaida, MD PhD, Naohiro Sekiguchi, MD PhD, Yusuke Tanetsugu, Kei Fukuhara, Masayuki Ohkura, Yuichiro Koide, Masayuki Hino, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4159.
https://doi.org/10.1182/blood-2019-121809
Published: 2019
Journal Articles

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Free
Tim H Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Camille Abboud, MD, Justin M. Watts, MD, Gianantonio Rosti, MD, Alexander Russell-Smith, Andrea Viqueira, MD, Arlene Reisman, Frank Giles, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4157.
https://doi.org/10.1182/blood-2019-124344
Published: 2019
Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Free
David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Naranie Shanmuganathan, MBBS FRACP FRCPA, Andrew Grigg, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, FRACP,FRCPA,PhD, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, David M Ross, MD PhD, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, MBBS FRACP FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP FRCPA, Nicholas Viiala, MBBS FRACP FRCPA, Robert Weinkove, MD, Agnes S. M. Yong, MD PhD, Deborah L. White, PhD FFSc (RCPA), Susan Branford, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2019) 134 (Supplement_1): 2926.
https://doi.org/10.1182/blood-2019-125740
Published: 2019
Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Free
Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2927.
https://doi.org/10.1182/blood-2019-132246
Published: 2019
Journal Articles

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Free
Hugues De Lavallade, Sophie Jackson, BSc, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Sebastian Francis, MBChB, MRCP, Edward Belsham, FRCPath, MB, Paul Cahalin, MA MRCP FRCPath, Joanne Ewing, PhDBMBS BSc FRPATH, Jenny Byrne, MD PhD, Kate Rothwell, BA MB BChir, PhD, Sandra Hassan, MBBS, MRCP, FRCPath, MDRes), Srinivas Pillai, MBBS,MD MRCP, FRCPath, Priyanka Mehta, Anshu Garg, MBBS,MDMRCP,FRCPath, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Oliver Ottmann, Prof, MD, Deepti Radia, Patrick Harrington, MRCP, FRCPath, Rachel Greig, Nicholas Lea, PhD, Michael Thompson, Aytug Kizilors, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2935.
https://doi.org/10.1182/blood-2019-129825
Published: 2019
Journal Articles

NUP98-HOXA9 -Initiates Molecular and Biologic Features of Disease Progression in a Humanized Model of CML

Free
Ivan Sloma, PharmD, PhD, Philip Beer, PhD FRCPath, MRCP, Christophe Desterke, PhD, Elizabeth Bulaeva, Misha Bilenky, Michelle Moksa, Kamini Raghuram, Cedric Brimacombe, Karen Lambie, Ali G Turhan, MD PhD, Orianne Wagner-Ballon, MD PhD, Philippe Gaulard, MD PhD, R. Keith Humphries, MD PhD, Martin Hirst, PhD BS, Connie J. Eaves, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4139.
https://doi.org/10.1182/blood-2019-127839
Published: 2019
Journal Articles

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

Free
David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Andrew Grigg, Naranie Shanmuganathan, MBBS FRACP FRCPA, Ann Christine Solterbeck, BSc(Hons) MSc PhDAstat, Deborah L. White, PhD FFSc (RCPA), Susan Branford, PhD FFSc (RCPA), Nicholas Viiala, MBBS FRACP FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K Mills, FRACP, FRCPA, MBBS, Jake Shortt, MBBS FRACP FRCPA PhD, Campbell Tiley, MBBS, FRACP, David M Ross, MD PhD, David Kipp, MBBS,FRCPA,FRACP, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, Ilona Cunningham, MBBS FRACP FRCPA, John Kwan, MBBS,FRACP,FRCPA, Richard Eek, MBChB MMED, FCP, FRACP., Howard Mutsando, MBChB FRACP FRCPA, Ken-Soon Tan, MMed FRACP MRCP(UK) MA MBBChir BA(Hons), Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2019) 134 (Supplement_1): 4150.
https://doi.org/10.1182/blood-2019-127619
Published: 2019
Journal Articles

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

Free
Matteo Emidio Dragani, MD, Giovanna Rege Cambrin, MD PhD, Paola Berchialla, PhD, Irene Dogliotti, MD, Gianantonio Rosti, MD, Fausto Castagnetti, MD PhD, Isabella Capodanno, MD, Marco Cerrano, MD, Dario Ferrero, MD, Monica Crugnola, MD, Chiara Elena, MD, Massimo Breccia, MD, Alessandra Iurlo, MD PhD, Daniele Cattaneo, MD, Sara Galimberti, MD PhD, Antonella Gozzini, MD, Monica Bocchia, Francesca Lunghi, MD, Michele Cedrone, MD, Nicola Sgherza, MD, Luigia Luciano, MD, Sabina Russo, MD, Marco Santoro, MD, Valentina Giai, MD, Giovanni Caocci, MD, Luciano Levato, MD, Elisabetta Abruzzese, MD, Federica Sora, MD, Giuseppe Saglio, MD, Carmen Fava
Journal: Blood
Blood (2019) 134 (Supplement_1): 4153.
https://doi.org/10.1182/blood-2019-129335
Published: 2019
Journal Articles

Investigations on Novel Gene Variants Associated with Longterm Response to Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia: Implication in TKI-Cessation Clinical Trails

Free
Zafar Iqbal, BSc, MSc, PhD, Muhammad Absar, BSc, MSc, PhD, Abid Jameel, MD PhD, Tanveer Akhtar, PhD, Sulman Basit, PhDMSc, Aamer Mahmood, PhD, Aamir Aleem, MBBS FRCP, Nawaf Alanazi, MBBS FRCPC, Ullah Anhar, Naila Batool Khalid, Sibtain Afzal, Jamil Amjad Hashmi, Afia M Akram, PhD, Khushnooda Ramzan, PhD, Mahmood Rasool, Muhammad Hasaan Aziz, Muhammad Farooq Sabar, PhD, Mudassar Iqbal, MDMS, Ahmad Mukhtar Khalid, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2939.
https://doi.org/10.1182/blood-2019-125518
Published: 2019
Journal Articles

High Throughput Immunophenotyping and Expression Profiling at Single Cell Level Reveal BCR-ABL1 Dependent Surface Markers of Chronic Myeloid Leukemia Stem Cells

Free
Marianna Romzova, PhD, Dagmar Smitalova, Peter Taus, Jiri Mayer, MD, Martin Culen, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2920.
https://doi.org/10.1182/blood-2019-126924
Published: 2019
Journal Articles

Multicolor Immunophenotyping of Candidate Leukemic Stem Cell Markers in CD34+CD38- Chronic Myeloid Leukemia Stem Cells

Free
Martin Culen, PhD, Marianna Romzova, PhD, Dagmar Smitalova, Tomas Loja, PhD, Jiri Mayer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2922.
https://doi.org/10.1182/blood-2019-127809
Published: 2019
Journal Articles

Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

Free
Hannah Asghari, MD BS, Chetasi Talati, MD, Alexandra Achille, John J. Powers, BS, Eva Sahakian, PhD, Onyee Chan, MD, Dawne N Shelton, PhD, Leidy Isenalumhe, MD, Lisa Nodzon, PhD ARNP, AOCNP, Kendra L. Sweet, MD, Javier Pinilla Ibarz, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3382.
https://doi.org/10.1182/blood-2019-131207
Published: 2019
Journal Articles

A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib

Free
Chung Hoow Kok, PhD BSc, Liu Liu, PhD BSc, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Verity A Saunders, Phuong Dang, Timothy P. Hughes, MDMBBS,FRACP,FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 663.
https://doi.org/10.1182/blood-2019-125446
Published: 2019
Journal Articles

Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors

Free
Roberto Latagliata, Imma Attolico, MD, Malgorzata Monika Trawinska, MD, Isabella Capodanno, MD, Mario Annunziata, MD, Chiara Elena, MD, Luigiana Luciano, Monica Crugnola, MD, Micaela Bergamaschi, MD, Massimiliano Bonifacio, MD, Claudia Baratè, Endri Mauro, MD, Gianni Binotto, MD, Nicola Sgherza, MD, Chiara Aguzzi, MD, Barbara Monteleone, MD, Federica Sorà, MD, Giovanni Caocci, MD, Debora Luzi, Elena Mariggiò, MD, Luigi Scaffidi, MD, Daniele Cattaneo, MD, Antonella Gozzini, MD, Ambra Di veroli, Sara Galimberti, MD PhD, Alessandra Iurlo, MD PhD, Massimo Breccia, MD, Giorgina Specchia, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1649.
https://doi.org/10.1182/blood-2019-127029
Published: 2019
Journal Articles

Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial

Free
Fernanda S Seguro, MD, Felipe VR Maciel, MD, Guilherme O Lopes, Luciana Nardinelli, M.Sc, Vanderson Rocha, MD PhD, Israel Bendit, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1651.
https://doi.org/10.1182/blood-2019-125989
Published: 2019
Journal Articles

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Free
B. Douglas Smith, MD, Tim H Brümmendorf, MD, Gail J. Roboz, MD, Carlo Gambacorti-Passerini, MD, Aude Charbonnier, Andrea Viquiera, Eric Leip, PhD, Frank Giles, MD, Thomas Ernst, MD, Andreas Hochhaus, MD, Gianantonio Rosti, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1650.
https://doi.org/10.1182/blood-2019-122230
Published: 2019
Journal Articles

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Free
Ana Beatriz Pascoal Lopes, Eliana C Miranda, PhD, Valquíria Mariane Oliveira Póvoa, Bruna Rocha Vergílio, Graziele Cristina Pavan Furlin, Marcia Torresan Delamain, MD, Gislaine Borba Duarte, MD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Katia B Pagnano, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1637.
https://doi.org/10.1182/blood-2019-128265
Published: 2019